Cue Biopharma, Inc. (CUE)
19.73
+0.31
(+1.60%)
USD |
NASDAQ |
Nov 03, 14:57
Cue Biopharma Enterprise Value : 92.97M for Nov. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 02, 2026 | 92.97M |
| October 30, 2026 | 100.55M |
| October 29, 2026 | 103.59M |
| October 28, 2026 | 102.07M |
| October 27, 2026 | 87.22M |
| October 26, 2026 | 87.90M |
| October 23, 2026 | 89.00M |
| October 22, 2026 | 90.20M |
| October 21, 2026 | 90.51M |
| October 20, 2026 | 80.52M |
| October 19, 2026 | 75.50M |
| October 16, 2026 | 78.80M |
| October 15, 2026 | 89.05M |
| October 14, 2026 | 88.68M |
| October 13, 2026 | 93.75M |
| October 12, 2026 | 120.11M |
| October 09, 2026 | 136.06M |
| October 08, 2026 | 108.19M |
| October 07, 2026 | 109.13M |
| October 06, 2026 | 112.42M |
| October 05, 2026 | 118.80M |
| October 02, 2026 | 125.13M |
| October 01, 2026 | 123.46M |
| September 30, 2026 | 126.70M |
| September 29, 2026 | 124.82M |
| Date | Value |
|---|---|
| September 28, 2026 | 134.96M |
| September 25, 2026 | 155.67M |
| September 24, 2026 | 163.20M |
| September 23, 2026 | 157.24M |
| September 22, 2026 | 153.00M |
| September 21, 2026 | 139.25M |
| September 18, 2026 | 185.16M |
| September 17, 2026 | 189.30M |
| September 16, 2026 | 170.10M |
| September 15, 2026 | 156.87M |
| September 14, 2026 | 151.17M |
| September 11, 2026 | 141.71M |
| September 10, 2026 | 137.84M |
| September 09, 2026 | 150.91M |
| September 08, 2026 | 148.30M |
| September 04, 2026 | 134.91M |
| September 03, 2026 | 136.11M |
| September 02, 2026 | 132.40M |
| September 01, 2026 | 140.14M |
| August 31, 2026 | 124.87M |
| August 28, 2026 | 137.21M |
| August 27, 2026 | 138.67M |
| August 26, 2026 | 142.28M |
| August 25, 2026 | 131.35M |
| August 24, 2026 | 112.63M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Cypherpunk Technologies, Inc. | 246.74M |
| Yarrow Bioscience, Inc. | -10.94M |
| Faeth Therapeutics, Inc. | 317.69M |
| Indaptus Therapeutics, Inc. | 454.79M |
| Pyxis Oncology, Inc. | 90.57M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -153.07M |
| Revenue (Quarterly) | 7.877M |
| Total Expenses (Quarterly) | 160.94M |
| EPS Diluted (Quarterly) | -24.14 |
| Gross Profit Margin (Quarterly) | 99.54% |
| Profit Margin (Quarterly) | -1.94K% |
| Earnings Yield | -136.9% |
| Normalized Earnings Yield | -150.57 |